Skip to main content

Take our TMF Risk Score Survey today!

Trial Interactive News & Press

Tuesday, March 10, 2015 | 3:40 PM

CTI Selects TransPerfect's Trial Interactive

CTI Selects TransPerfect's Trial Interactive Platform as its eTMF and Study Start-Up Solution. eClinical Solution Enables CTI to Move to a Paperless Global Trial Management Process

NEW YORK, NY, March 10, 2015 – TransPerfect, a leading provider of global development and commercialization solutions to the life sciences industry, today announced that CTI Clinical Trial and Consulting Services (CTI) has implemented Trial Interactive as its electronic Trial Master File (eTMF) and study start-up solution to streamline global trial management for its development programs.

Trial Interactive is a web-based, 21 CFR Part 11 compliant platform that eliminates the redundancies inherent in paper-based study start-up and TMF management. By providing study stakeholders with real-time access to clinical trial documentation, Trial Interactive cuts out the travel and shipping costs associated with paper review and reconciliation, consolidating clinical trial documentation processes for CTI and its sponsors. With modules for study start-up and eTMF, Trial Interactive offers CTI an end-to-end e-clinical solution.

“At CTI approximately 80% of our studies meet or exceed enrollment expectations, despite the challenging patient populations we work in, which is due in part to our excellent pre-trial and start-up processes,” stated Kevin Schwarz, Chief Operating Officer, CTI. “With its automation and global document management capabilities, Trial Interactive helps us streamline our study management process while meeting regulatory requirements, allowing for remote inspections and even faster start-up timelines.”

“We chose the Trial Interactive platform because it is a true paperless application that delivers the innovation and anytime/anywhere accessibility we need in order to serve our nearly one hundred clients in the pharmaceutical and biotechnology industry,” added Louis Minham, Senior Director, Information Technology, CTI.

Michael Smyth, General Manager of TransPerfect Life Sciences Solutions, stated, “We are excited to have been chosen as a strategic partner of CTI to help them move towards a virtual clinical development program that will meet regulatory requirements. We appreciate that they see the value of the solution, not only for CTI and their sponsors, but for investigative site personnel who will benefit greatly from the added efficiencies it offers.”

About Trial Interactive

TransPerfect’s Trial Interactive solution provides a collaborative, web-based platform for clinical development that enables sponsors, CROs, IRBs, and other vendors to maintain and update clinical trial documentation in a secure online environment, adhering to global regulatory requirements. With fully searchable solutions including investigator portals, Trial Interactive streamlines study timelines and reduces the administrative burdens of global clinical trials. As part of TransPerfect’s Life Sciences division, Trial Interactive is dedicated to working with clients on a global, collaborative level, supporting a wide range of requirements including e-feasibility, study start-up, eTMF review/reconciliation, mobile applications, learning management and document management systems, investigator portals, pharmacovigilance and safety management, and endpoint adjudication. For more information on Trial Interactive, please contact or +1 212.400.8848, or visit

About TransPerfect

TransPerfect is the world’s largest provider of language services and technology solutions for global business. From offices in over 90 cities on six continents, TransPerfect offers a full range of services in 170+ languages to clients worldwide. More than 4,000 global organizations employ TransPerfect’s GlobalLink® Product Suite to simplify management of multilingual content. With an unparalleled commitment to quality and client service, TransPerfect is fully ISO 9001 and ISO 17100 certified. TransPerfect has global headquarters in New York, with regional headquarters in London and Hong Kong. For more information, please visit our website at

Back to News